You may also be interested in...
Adjuvant celecoxib not associated with improved disease-free survival in patients with ERBB2-negative breast cancer
#VisualAbstract Addition of daratumumab to standard of care improves minimal residual disease negativity in patients with newly diagnosed, transplant-ineligible multiple myeloma
Some people who have cholangiocarcinoma are now set to benefit from life-extending treatment pemigatinib after NICE published final draft guidance recommending it.
Ipatasertib plus abiraterone significantly improves survival in patients with PTEN-negative prostate cancer compared to abiraterone alone